Scinai Immunotherapeutics (NASDAQ: SCNI) has secured a definitive development and clinical manufacturing agreement valued at approximately $5.1 million in committed base service fees through its wholly owned subsidiary, Scinai Biopharma Services Ltd. The agreement, signed with a U.S.-based, Nasdaq-listed biopharmaceutical company, expands an existing customer relationship and covers development and clinical manufacturing services for an investigational oncology product. Revenue from the contract is expected to be recognized during 2026 and 2027, with stability services extending beyond 2027. The deal underscores the growing demand for Scinai's contract development and manufacturing organization (CDMO) capabilities and provides a significant revenue backlog for the coming years.
The impact of this agreement is immediately visible in Scinai's order book. Following the deal, the company's committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million. This represents a 300% increase from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. Such rapid growth in committed orders highlights the company's ability to attract and retain clients in the competitive CDMO space. The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones. If realized, these opportunities could further bolster Scinai's long-term revenue trajectory.
Scinai Immunotherapeutics operates a dual-pronged business model: a growing CDMO and an immunology-focused therapeutic development platform. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. This agreement with a Nasdaq-listed biopharma company not only validates Scinai's manufacturing expertise but also strengthens its position as a reliable partner for biotechnology and pharmaceutical companies. For investors, the news signals execution on the CDMO strategy and provides greater visibility into future cash flows. The latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI.
To view the full press release, visit https://ibn.fm/5jaNp. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of social media followers.
